The TGA might just be asking the normal questions about the obvious gaps in the AnteoTech application. Reading any of the published patient information sheets for approved OTC tests make it obvious that TGA needs the manufacturer to makes some statements backed with some data on variants. If the AnteoTech application did not ... well ...!
Anyway - the average shareholder was more interested in ensuring we had a marketing manager rather than a regulatory expert on staff. So we just take a slow route of waiting for the TGA questions rather than anticipating them.
The TGA might just be asking the normal questions about the...
-
- There are more pages in this discussion • 2,156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |